Learnings From Key Clinical Trials in Ovarian Cancer

Video content is prompted by the following:

Lessons From Recent Clinical Trials

Key Discussion Points:

• Biomarker-Driven Treatment Selection
• Current challenge of selecting from multiple approved therapies with overlapping biomarkers

• Need for predictive power of biomarkers beyond simple positivity (eg, understanding implications of HER2 2+ vs folate medium expression)

• Sequencing implications of therapies with overlapping toxicity profiles
• Treatment Sequencing Considerations
• Critical importance of first therapy selection in platinum-resistant setting given patient drop-off with subsequent lines

• Limited understanding of how different biomarkers interact (BRCA, HRD, CCNE1, HER2, folate receptor)

• Patient-specific factors influencing treatment selection beyond biomarker status
• Evolution of Clinical Trial Design
• Moving away from “spray and pray” approaches with all-comers to biomarker-driven selection

• Learning from past experiences with immunotherapy trials that enrolled thousands without clear biomarker strategy

• Need for smarter trial designs that enable more precise patient selection

Notable Insights:

1. “Which one do I start with? Do I start with trastuzumab deruxtecan or do I start with mirvetuximab and bevacizumab?... Right now, we’re guessing.”
2. “We’ve said forever, ‘We don’t have mutations, and we don’t have anything to target.’ We have a lot of things to target. We just are at the early days of figuring out what it means.”
3. “3,000-plus patients exposed to 4 different sponsors’ frontline studies of immunotherapy and PARP...can’t do that again...I think we’ve learned that lesson, and we’re going to do better moving forward.”